Recently stock market analysts have updated their consensus ratings on shares of Axsome Therapeutics, Inc. (AXSM). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/30/2016 – Axsome Therapeutics, Inc. had its “buy” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

12/17/2015 – Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 29 price target on the stock.

12/15/2015 – Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 13 price target on the stock.

Axsome Therapeutics, Inc. has a 50 day moving average of 9.86 and a 200 day moving average of 9.34. The stock’s market capitalization is 126.30M, it has a 52-week low of 5.37 and a 52-week high of 15.74.

The share price of the company (AXSM) was up +1.52% during the last trading session, with a high of 11.59 and the volume of Axsome Therapeutics, Inc. shares traded was 15584.

View other investors thoughts on Axsome Therapeutics, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.